Immunome, Inc.

General Information
We are a biopharmaceutical company using our proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. Our primary focus is oncology (cancer) but our technology may also have applications in the discovery of new therapeutics for infectious diseases, including COVID-19.
Our leading discovery program targets interleukin-38, a small protein,secreted by various cells of the body, which appears to function as a novel immune checkpoint inhibitor.
We entered into an agreement with the U.S. Department of Defense in July 2020 to develop a BCP product candidate for the potential treatment and prevention of SARS-CoV-2 infections, including COVID-19. (BCP is an acronym for biosynthetic convalescent plasma.)
Industry: Pharmaceuticals
Employees: 21
Founded: 2006
Contact Information
Address 665 Stockton Drive, Suite 300 Exton, PA 19341
Phone Number (610) 321-3700
Web Address
View Prospectus: Immunome, Inc.
Financial Information
Market Cap
Revenues $0 mil (last 12 months)
Net Income $-8.5 mil (last 12 months)
IPO Profile
Symbol IMNM
Exchange NASDAQ
Shares (millions): 0.0
Price range $0.00 - $0.00
Est. $ Volume $30.0 mil
Manager / Joint Managers Ladenburg Thalmann/ Chardan
Expected To Trade:
Status: TBA
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change